Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-248 + Azacitidine in Myeloid Malignancies
NCT06656494Phase 1Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of mesutoclax in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by InnoCare Pharma. Primary endpoints: Dose-Limiting Toxicity at 2.5 years, Recommended Phase II Dose / Maximum Tolerated Dose at 2.5 years and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
mesutoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06656494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656494.